Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 41.14% | 26.90% | 50.02% | 39.73% | 44.34% |
| Total Depreciation and Amortization | -50.00% | 50.57% | -94.08% | -94.47% | -82.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -44.73% | 203.61% | -75.00% | 90.94% | 103.42% |
| Change in Net Operating Assets | -46.82% | 147.81% | -88.65% | 104.34% | -245.31% |
| Cash from Operations | 20.62% | 60.97% | 16.14% | 46.48% | 35.16% |
| Capital Expenditure | -- | -- | 289.80% | 91.86% | -143.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 117.32% | 225.00% | 289.80% | 91.86% | -143.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -93.94% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -93.94% | -- | -100.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.80% | 61.14% | 17.13% | 48.06% | 33.55% |
